A Multicentre, multi-arm, non-randomised, Phase 1b dose escalation Study of Teclistamab for newly diagnosed or relapsed/refractory MM. (NCT03145181)
MajesTEC-2
This trial is No longer recruiting
Registration number NCT03145181
Program & service
This trial is being run with the Cancer service, and as part of the Haematology program.
Trial phase
Phase 1
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor Andrew Spencer
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR